Yangliang Ye

State Key Laboratory Of Drug Research
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Small molecule inhibits KCNQ channels with a non-blocking mechanism.

Small molecule inhibits KCNQ channels with a non-blocking mechanism.

Journal: Nature chemical biology

Published: July 30, 2024

Discovery of a novel GPR35 agonist with high and equipotent species potency for oral treatment of IBD.

Discovery of a novel GPR35 agonist with high and equipotent species potency for oral treatment of IBD.

Journal: Bioorganic & medicinal chemistry

Published: August 09, 2023

A small-molecule activation mechanism that directly opens the KCNQ2 channel.

A small-molecule activation mechanism that directly opens the KCNQ2 channel.

Journal: Nature chemical biology

Published: March 03, 2023

Phenotypic screening-based drug discovery of furan-2-carboxylic acid derivatives for the amelioration of type 2 diabetes mellitus (T2DM).

Phenotypic screening-based drug discovery of furan-2-carboxylic acid derivatives for the amelioration of type 2 diabetes mellitus (T2DM).

Journal: European journal of medicinal chemistry

Published: October 14, 2022

General Pharmacological Activation Mechanism of K+ Channels Bypassing Channel Gates.

General Pharmacological Activation Mechanism of K+ Channels Bypassing Channel Gates.

Journal: Journal of medicinal chemistry

Published: July 25, 2022

Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio.

Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio.

Journal: Bioorganic & medicinal chemistry

Published: February 15, 2021

Design of G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) soft drugs with reduced gallbladder-filling effects.

Design of G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) soft drugs with reduced gallbladder-filling effects.

Journal: European journal of medicinal chemistry

Published: January 21, 2020

TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice.

TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice.

Journal: Metabolism: clinical and experimental

Published: March 13, 2019

Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker.

Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker.

Journal: European journal of medicinal chemistry

Published: January 31, 2018

Linderane Suppresses Hepatic Gluconeogenesis by Inhibiting the cAMP/PKA/CREB Pathway Through Indirect Activation of PDE 3 via ERK/STAT3.

Linderane Suppresses Hepatic Gluconeogenesis by Inhibiting the cAMP/PKA/CREB Pathway Through Indirect Activation of PDE 3 via ERK/STAT3.

Journal: Frontiers in pharmacology

Published: November 15, 2017

Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes.

Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes.

Journal: Journal of medicinal chemistry

Published: February 25, 2015

Design, synthesis, and structure-activity relationships of 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazoles as TGR5 agonists.

Design, synthesis, and structure-activity relationships of 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazoles as TGR5 agonists.

Journal: ChemMedChem

Published: April 02, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026